Upgrade to SI Premium - Free Trial

TD Cowen: 'AstraZeneca's (AZN) history of innovation offers opportunity for upside'

March 18, 2026 9:24 AM
(Updated - March 18, 2026 9:26 AM EDT)

TD Cowen analyst Steve Scala reiterated a Buy rating and $240.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments